Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Medicine (Baltimore). 2021 Jan 29;100(4):e24307. doi: 10.1097/MD.0000000000024307.
Myelosuppression after chemotherapy is a common adverse reaction in the process of chemotherapy, mainly manifested as anemia, increased risk of bleeding, infection, the results seriously affect the quality of life and prognosis of patients, become the main cause of death. Since ancient times, traditional Chinese medicine (TCM) has been widely used in East Asia (such as China, Japan, South Korea) in the clinical treatment of bone marrow suppression after chemotherapy, which plays the role of synergism, toxicity reduction, immune regulation, and gradually developed into an indispensable role. Therefore, the purpose of this study was to use a network meta-analysis to evaluate the evidence that traditional Chinese medicine is related to the efficacy and safety of chemotherapy-induced myelosuppression.
This study will search the following Chinese and English databases electronically: 4 Chinese literature databases, including China biology and medicine database, China National Knowledge Infrastructure, VIP, and Wan fang database, and 3 British literature databases including PubMed, EMBASE, and Cochrane Library. The search keywords were (traditional Chinese medicine or medicinal plants or extracts of traditional Chinese medicine or traditional Chinese medicine formula or preparation) and (myelosuppression after chemotherapy) and (randomized controlled trials) (RCTs). The search time limit is set to December 2020, and Chinese and English languages will be included. The included subjects must be diagnosed with myelosuppression after chemotherapy and RCTs should be conducted at the same time. The main outcome was elevated hemoglobin, platelets, leukocytes, and neutrophils. The secondary results were reticulocyte absolute value, reticulocyte percentage, low-fluorescence reticulocyte red, medium-fluorescent reticulocyte red, and high-fluorescence reticulocyte red. We will conduct a risk and quality assessment of the included studies using the Cochrane tool, and carefully calculate data synthesis after meta-analysis using Rev Man software (version 5.3.5) and R software (version 3.6.1).
The study is aim to evaluate the efficacy and safety of the treatment that traditional Chinese medicine for myelosuppression after chemotherapy.
This study of the meta-analysis could provide evidence for clinicians and help patients to make a better choice.
INPLASY2020120097.
化疗后骨髓抑制是化疗过程中的一种常见不良反应，主要表现为贫血、出血风险增加、感染，其结果严重影响患者的生活质量和预后，成为死亡的主要原因。自古以来，中医药（TCM）在东亚（如中国、日本、韩国）的临床治疗中广泛应用于化疗后骨髓抑制，发挥协同作用、降低毒性、免疫调节等作用，逐渐发展成为不可或缺的作用。因此，本研究旨在采用网络荟萃分析评估中医药治疗化疗后骨髓抑制疗效和安全性的证据。
本研究将通过电子方式检索以下中文和英文数据库：4 个中文文献数据库，包括中国生物医学数据库、中国国家知识基础设施、维普和万方数据库，以及 3 个英文文献数据库，包括 PubMed、EMBASE 和 Cochrane Library。检索关键词为（中药或药用植物或中药提取物或中药方剂或制剂）和（化疗后骨髓抑制）和（随机对照试验）（RCTs）。搜索时间限定为 2020 年 12 月，包括中文和英文语言。纳入的研究对象必须诊断为化疗后骨髓抑制，同时进行 RCT。主要结局为血红蛋白升高、血小板升高、白细胞升高和中性粒细胞升高。次要结果为网织红细胞绝对值、网织红细胞百分比、低荧光网织红细胞红、中荧光网织红细胞红和高荧光网织红细胞红。我们将使用 Cochrane 工具对纳入研究进行风险和质量评估，并在荟萃分析后使用 RevMan 软件（版本 5.3.5）和 R 软件（版本 3.6.1）仔细计算数据合成。
本研究旨在评估中医药治疗化疗后骨髓抑制的疗效和安全性。
本荟萃分析研究可为临床医生提供证据，并帮助患者做出更好的选择。
INPLASY 注册号：INPLASY2020120097。
